Related Experiment Video
Updated: Jul 11, 2026
07:08
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Adjuvant therapy for pancreatic cancer
Kyaw L Aung1, David B Smith, J P Neoptolemos
1Clatterbridge Centre for Oncology, Bebington, Wirral, Merseyside, CH63 4JY, UK. kyan.aung@ccotrust.nhs.uk
Expert Opinion on Pharmacotherapy
|October 13, 2007
Summary
Pancreatic cancer survival is improving with advances in surgical techniques and adjuvant chemotherapy. Treatments like 5-fluorouracil and gemcitabine show significant benefits for patients with pancreatic ductal adenocarcinoma.
Area of Science:
- Oncology
- Gastroenterology
- Surgical Oncology
Background:
- Pancreatic ductal adenocarcinoma is a leading cause of cancer mortality globally.
- Historically, treatment options for pancreatic cancer offered limited success, with high rates of early relapse after surgery and unproven adjuvant therapies.
- Systemic therapy for advanced pancreatic cancer provided only short-term benefits.
Purpose of the Study:
- To review the evolving treatment landscape for pancreatic ductal adenocarcinoma.
- To evaluate the impact of recent advancements in surgical and adjuvant therapies on patient survival.
- To assess the efficacy of novel agents in managing this disease.
Main Methods:
- Review of current literature on pancreatic cancer treatment.
- Analysis of survival data for adjuvant chemotherapy regimens (5-fluorouracil/folinic acid, gemcitabine).
- Evaluation of emerging therapies like capecitabine and erlotinib.
Main Results:
- Specialist surgery has improved outcomes for pancreatic cancer patients.
- Adjuvant chemotherapy, specifically 5-fluorouracil with folinic acid, significantly increases 5-year survival rates (up to 29% vs. 11%).
- Adjuvant gemcitabine improves disease-free survival, but not overall survival. Adjuvant chemoradiation's role is unproven and potentially inferior to chemotherapy alone.
Conclusions:
- Adjuvant chemotherapy offers a significant survival advantage for pancreatic ductal adenocarcinoma.
- While challenges remain, emerging agents like capecitabine and erlotinib show promise for future treatment strategies.
- Continued research and specialized care are crucial for improving outcomes in pancreatic cancer.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...